WO2002070070A3 - Compositions having improved bioavailability of eletriptan - Google Patents

Compositions having improved bioavailability of eletriptan Download PDF

Info

Publication number
WO2002070070A3
WO2002070070A3 PCT/IB2002/000512 IB0200512W WO02070070A3 WO 2002070070 A3 WO2002070070 A3 WO 2002070070A3 IB 0200512 W IB0200512 W IB 0200512W WO 02070070 A3 WO02070070 A3 WO 02070070A3
Authority
WO
WIPO (PCT)
Prior art keywords
eletriptan
compositions
improved bioavailability
inhibitor
bioavailabilty
Prior art date
Application number
PCT/IB2002/000512
Other languages
French (fr)
Other versions
WO2002070070A2 (en
Inventor
Michael John Humphrey
Original Assignee
Pfizer Ltd
Michael John Humphrey
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Michael John Humphrey, Pfizer filed Critical Pfizer Ltd
Priority to BR0207751-5A priority Critical patent/BR0207751A/en
Priority to EP02712162A priority patent/EP1372785A2/en
Priority to MXPA03007836A priority patent/MXPA03007836A/en
Priority to CA002439917A priority patent/CA2439917A1/en
Priority to JP2002569239A priority patent/JP2004529893A/en
Priority to AU2002232061A priority patent/AU2002232061A1/en
Publication of WO2002070070A2 publication Critical patent/WO2002070070A2/en
Publication of WO2002070070A3 publication Critical patent/WO2002070070A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The bioavailabilty of eletriptan can be increased by co-administering eletriptan with a p-glycoprotein (p-gp) inhibitor. The eletriptan and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit.
PCT/IB2002/000512 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan WO2002070070A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0207751-5A BR0207751A (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability
EP02712162A EP1372785A2 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan
MXPA03007836A MXPA03007836A (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability.
CA002439917A CA2439917A1 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan
JP2002569239A JP2004529893A (en) 2001-03-01 2002-02-20 Compositions with improved bioavailability
AU2002232061A AU2002232061A1 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105131.7A GB0105131D0 (en) 2001-03-01 2001-03-01 Compositions having improved bioavailability
GB0105131.7 2001-03-01

Publications (2)

Publication Number Publication Date
WO2002070070A2 WO2002070070A2 (en) 2002-09-12
WO2002070070A3 true WO2002070070A3 (en) 2003-04-10

Family

ID=9909814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000512 WO2002070070A2 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan

Country Status (8)

Country Link
EP (1) EP1372785A2 (en)
JP (1) JP2004529893A (en)
AU (1) AU2002232061A1 (en)
BR (1) BR0207751A (en)
CA (1) CA2439917A1 (en)
GB (1) GB0105131D0 (en)
MX (1) MXPA03007836A (en)
WO (1) WO2002070070A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409127A (en) * 2003-04-11 2006-03-28 Pfizer pharmaceutical combination comprising electriptan and sodium bicarbonate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2325161A (en) * 1997-05-14 1998-11-18 Merck Sharp & Dohme Pharmaceutical formulation comprising a 5-HT agonist and an anti-emetic and/or gasto-prokinetic agent
WO2000025778A1 (en) * 1998-10-30 2000-05-11 Pfizer Products Inc. 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2325161A (en) * 1997-05-14 1998-11-18 Merck Sharp & Dohme Pharmaceutical formulation comprising a 5-HT agonist and an anti-emetic and/or gasto-prokinetic agent
WO2000025778A1 (en) * 1998-10-30 2000-05-11 Pfizer Products Inc. 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.ALLEN E.A.: "Pharmacology and efficacy of eletriptan for the treatment of migraine attacks", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol. 55, no. 5, 2001, pages 346 - 347, XP008011784 *

Also Published As

Publication number Publication date
CA2439917A1 (en) 2002-09-12
BR0207751A (en) 2004-03-09
WO2002070070A2 (en) 2002-09-12
GB0105131D0 (en) 2001-04-18
JP2004529893A (en) 2004-09-30
MXPA03007836A (en) 2003-12-08
AU2002232061A1 (en) 2002-09-19
EP1372785A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
WO2005102392A3 (en) Combinations for treating hiv infection
WO2006031878A3 (en) Imidazoquinoline compounds
WO2003054146A3 (en) Self-assembly and mineralization of peptide-amphiphile nanofibers
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2003289440A1 (en) Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
AU2003287726A1 (en) Intraocular delivery compositions and methods
AU2002347614A1 (en) Antioxidant combination composition and use thereof
WO2006007671A3 (en) Therapeutically combinations
EP1127580A3 (en) Method of increasing the bioavailability and tissue penetration of azithromycin
AU2003240058A1 (en) Compositions comprisins vitamin k
AU2003270389A1 (en) Composition containing feverfew extract and use thereof
AU2003261053A1 (en) Fuel additive composition and its preparation
AU2002360547A1 (en) Monoterpene compositions and uses thereof
AUPS329002A0 (en) Glycoalkaloid compositions and various uses thereof
AU2002242777A1 (en) Novel fungicide compositions based on pyridylmethylbenzamide and propamocarb derivative
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU2001270310A1 (en) Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
WO2002070070A3 (en) Compositions having improved bioavailability of eletriptan
AU2003272717A1 (en) Frozen spermatozoa compositions and uses thereof
AU2003202550A1 (en) Pharmaceutical formulations with modified release
WO2005062874A3 (en) Compounds and compositions for delivering active agents
AU2003228305A1 (en) Pharmaceutical composition with combined active agents and methods for using the same
AU2002332244A1 (en) Demelanizing agents, beautifying agents, demelanizing compositions and beautifying compositions
WO2004111088A3 (en) Angiogenic factor and inhibitors thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002712162

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002569239

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007836

Country of ref document: MX

Ref document number: 2439917

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002712162

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002712162

Country of ref document: EP